PortalPublikationenOvarian cancer--can intraperitoneal therapy be regarded as n...

Ovarian cancer--can intraperitoneal therapy be regarded as new standard in Germany?

Standard

Ovarian cancer--can intraperitoneal therapy be regarded as new standard in Germany? / du Bois, A; Schmalfeldt, B; Meier, W; Sehouli, J; Pfisterer, J; Arbeitsgemeinschaft Gynaekologische Onkologie [AGO] Kommission OVAR.

in: INT J GYNECOL CANCER, Jahrgang 16, Nr. 5, 03.10.2006, S. 1756-60.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

du Bois, A, Schmalfeldt, B, Meier, W, Sehouli, J, Pfisterer, J & Arbeitsgemeinschaft Gynaekologische Onkologie [AGO] Kommission OVAR 2006, 'Ovarian cancer--can intraperitoneal therapy be regarded as new standard in Germany?', INT J GYNECOL CANCER, Jg. 16, Nr. 5, S. 1756-60. https://doi.org/10.1111/j.1525-1438.2006.00712.x

APA

du Bois, A., Schmalfeldt, B., Meier, W., Sehouli, J., Pfisterer, J., & Arbeitsgemeinschaft Gynaekologische Onkologie [AGO] Kommission OVAR (2006). Ovarian cancer--can intraperitoneal therapy be regarded as new standard in Germany? INT J GYNECOL CANCER, 16(5), 1756-60. https://doi.org/10.1111/j.1525-1438.2006.00712.x

Vancouver

du Bois A, Schmalfeldt B, Meier W, Sehouli J, Pfisterer J, Arbeitsgemeinschaft Gynaekologische Onkologie [AGO] Kommission OVAR. Ovarian cancer--can intraperitoneal therapy be regarded as new standard in Germany? INT J GYNECOL CANCER. 2006 Okt 3;16(5):1756-60. https://doi.org/10.1111/j.1525-1438.2006.00712.x

Bibtex

@article{7401a70c74274343bd1f4cfa2de495c9,
title = "Ovarian cancer--can intraperitoneal therapy be regarded as new standard in Germany?",
abstract = "The German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) and the two German cooperative study groups (AGO-OVAR and NOGGO) performed a review of the currently available literature on intraperitoneal first-line treatment in advanced ovarian cancer to consider if this new option should be incorporated into the German guidelines for treatment of ovarian cancer.",
keywords = "Antineoplastic Agents, Clinical Trials as Topic, Female, Germany, Humans, Infusions, Parenteral, Ovarian Neoplasms, Practice Guidelines as Topic",
author = "{du Bois}, A and B Schmalfeldt and W Meier and J Sehouli and J Pfisterer and {Arbeitsgemeinschaft Gynaekologische Onkologie [AGO] Kommission OVAR}",
year = "2006",
month = oct,
day = "3",
doi = "10.1111/j.1525-1438.2006.00712.x",
language = "English",
volume = "16",
pages = "1756--60",
journal = "INT J GYNECOL CANCER",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

RIS

TY - JOUR

T1 - Ovarian cancer--can intraperitoneal therapy be regarded as new standard in Germany?

AU - du Bois, A

AU - Schmalfeldt, B

AU - Meier, W

AU - Sehouli, J

AU - Pfisterer, J

AU - Arbeitsgemeinschaft Gynaekologische Onkologie [AGO] Kommission OVAR

PY - 2006/10/3

Y1 - 2006/10/3

N2 - The German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) and the two German cooperative study groups (AGO-OVAR and NOGGO) performed a review of the currently available literature on intraperitoneal first-line treatment in advanced ovarian cancer to consider if this new option should be incorporated into the German guidelines for treatment of ovarian cancer.

AB - The German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) and the two German cooperative study groups (AGO-OVAR and NOGGO) performed a review of the currently available literature on intraperitoneal first-line treatment in advanced ovarian cancer to consider if this new option should be incorporated into the German guidelines for treatment of ovarian cancer.

KW - Antineoplastic Agents

KW - Clinical Trials as Topic

KW - Female

KW - Germany

KW - Humans

KW - Infusions, Parenteral

KW - Ovarian Neoplasms

KW - Practice Guidelines as Topic

U2 - 10.1111/j.1525-1438.2006.00712.x

DO - 10.1111/j.1525-1438.2006.00712.x

M3 - SCORING: Journal article

C2 - 17009967

VL - 16

SP - 1756

EP - 1760

JO - INT J GYNECOL CANCER

JF - INT J GYNECOL CANCER

SN - 1048-891X

IS - 5

ER -